PeptideCompareN-Acetyl Semax — EU research guide.
N-Acetyl Semax is an acetylated analogue of Semax (ACTH 4–7 Pro-Gly-Pro) with proposed enhanced CNS penetration, longer duration of action and more pronounced BDNF-stimulating effects than the parent compound.
What is N-Acetyl Semax?
The acetylation of Semax's N-terminus increases its resistance to aminopeptidase degradation, extending the effective window of activity. The primary mechanism remains ACTH-receptor-independent BDNF and NGF upregulation in prefrontal cortex and hippocampus, with additional serotonergic and dopaminergic modulation.
What does the research show?
Like N-Acetyl Selank, direct clinical research on N-Acetyl Semax is sparse. The pharmacological rationale derives from acetylation studies on other neuropeptides showing improved stability. Comparative animal studies suggest enhanced and extended cognitive effects versus Semax at equivalent doses. No head-to-head human trials published as of mid-2026.
EU legal status
Not approved anywhere. Available from EU research vendors. Same considerations as parent Semax apply — most relevant Russian research concerns the non-acetylated form.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
N-Acetyl Semax across EU suppliers
COA-verified EU vendors · Updated monthly